Aduro BioTech Inc (NASDAQ:ADRO) COO Gregory W. Schafer sold 20,000 shares of Aduro BioTech stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $9.34, for a total value of $186,800.00. Following the sale, the chief operating officer now directly owns 155,676 shares in the company, valued at $1,454,013.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Aduro BioTech Inc (ADRO) traded down $0.50 during mid-day trading on Monday, hitting $9.05. 648,624 shares of the stock traded hands, compared to its average volume of 407,337. Aduro BioTech Inc has a 1 year low of $6.01 and a 1 year high of $14.05.
Aduro BioTech (NASDAQ:ADRO) last released its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). Aduro BioTech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The business had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $4.04 million. During the same quarter in the previous year, the business posted ($0.54) earnings per share. Aduro BioTech’s revenue for the quarter was up .0% on a year-over-year basis. sell-side analysts predict that Aduro BioTech Inc will post -1.28 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc lifted its holdings in shares of Aduro BioTech by 11.2% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 1,043 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Aduro BioTech during the third quarter valued at approximately $127,000. Parametric Portfolio Associates LLC lifted its holdings in shares of Aduro BioTech by 15.9% during the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 2,119 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Aduro BioTech during the third quarter valued at approximately $167,000. Finally, Trexquant Investment LP purchased a new position in shares of Aduro BioTech during the third quarter valued at approximately $175,000. Hedge funds and other institutional investors own 45.19% of the company’s stock.
Several analysts have weighed in on the company. BidaskClub cut Aduro BioTech from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. HC Wainwright set a $18.00 price objective on Aduro BioTech and gave the company a “buy” rating in a research report on Tuesday, October 17th. William Blair reaffirmed an “outperform” rating on shares of Aduro BioTech in a research report on Monday, October 2nd. Finally, Oppenheimer assumed coverage on Aduro BioTech in a research report on Monday, October 30th. They set a “buy” rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $19.14.
ILLEGAL ACTIVITY NOTICE: “Aduro BioTech Inc (ADRO) COO Gregory W. Schafer Sells 20,000 Shares” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/12/04/aduro-biotech-inc-adro-coo-gregory-w-schafer-sells-20000-shares-2.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech Inc and related companies with MarketBeat.com's FREE daily email newsletter.